VIDEO: Apellis releases 3-year data on pegcetacoplan for geographic atrophy
Click Here to Manage Email Alerts
In this video, Yasha S. Modi, MD, discusses 3-year data from the GALE extension study on pegcetacoplan for the treatment of geographic atrophy, presented at the American Academy of Ophthalmology meeting.
The data showed that there was continued separation between the treatment arm and the sham arm, Modi said.
“What was interesting was they crossed over patients who were previously receiving sham, and the slope of that geographic atrophy progression diminished, which was very exciting to see,” Modi, associate professor, department of ophthalmology at NYU Grossman School of Medicine, said.
Modi noted that the research indicated that the slope of geographic atrophy progression was slowing every 6 months.
“But as you get from 24 to 30 months and then 30 to 36 months, I was hoping to see a little bit more flattening of that line, which we ultimately did not see,” he said. “So clearly, even at 3 years, we see progression of geographic atrophy in patients who are receiving pegcetacoplan given every month or every other month.”
Reference:
- Heier J, et al. GALE 12-month data: First-time presentation of full cohort. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts